Drugs / vobramitamab duocarmazine
vobramitamab duocarmazine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05293496 | Apr 2022 → Jun 2025 | castration-resistant prostate carcinoma, hepatocellular carcinoma, malignant epithelial tumor of ovary, melanoma +2 | MacroGenics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03729596 | Nov 2018 → Mar 2023 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, prostate carcinoma +1 | MacroGenics | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06227546 | Apr 2024 → Mar 2025 overdue | small cell lung carcinoma | Georgetown University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05551117 | Jun 2023 → Jul 2024 | anal carcinoma, castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma, laryngeal squamous cell carcinoma +4 | MacroGenics | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vobramitamab duocarmazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293496 ↗ |
| Known as | AEX4089DC1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594576 ↗ |
| Known as | MGC018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06227546 ↗ |
| Known as | Vobramitamab duocarmazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594576 ↗ |
| Modality | Other / unclassified | “Anti-B7H3 antibody drug conjugate” NCT03729596 ↗ |
| Route | Intravenous | “0.5 mg/kg IV every 3 weeks” NCT03729596 ↗ |